EPIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that ESSA Pharma Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ESSA Pharma Inc. (“ESSA” or “the Company”) (
NASDAQEPIX) and certain of its officers.
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA PharmaFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ESSA Pharma To Contact Him Directly To Discuss Their Options
ESSA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ESSA Pharma Inc. and Encourages Investors to Contact the FirmNEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against ESSA Pharma Inc. (“ESSA” or the “Company”) (
NASDAQEPIX) in the United States District Court for the Eastern District of Wisconsin on behalf of all persons and entities who purchased or otherwise acquired ESSA securities between December 12, 2023 and October 31, 2024, both dates inclusive (the “Class Period”). Investors have until March 25, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
EPIX Investor Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against ESS Pharma Inc.SAN DIEGO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired ESSA Pharma Inc. (
NASDAQEPIX) securities between December 12, 2023 and October 31, 2024. ESSA is a clinical stage pharmaceutical company that focuses on the development of small molecule drugs for the treatment of prostate cancer. The Company's lead product candidate was masofaniten, which was in clinical trial in combination with enzalutamide compared with enzalutamide alone in patients with metastatic CRPC.
EPIX Investors Have Opportunity to Lead ESSA Pharma Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ESSA Pharma Inc. (“ESSA” or “the Company”) (
NASDAQEPIX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Rosen Law Firm Urges ESSA Pharma Inc. (NASDAQ: EPIX) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers and acquirers of securities of ESSA Pharma Inc. (
NASDAQEPIX) between December 12, 2023 and October 31, 2024, inclusive (the “Class Period”). The lawsuit describes ESSA as a “clinical stage pharmaceutical company that focuses on the development of small molecular drugs for the treatment of prostate cancer.”
